What You Should Know
– Xella Health has emerged from stealth with $3.7M in pre-seed financing to build the infrastructure for “decoding” female biology.
– Led by Precursor Ventures, the company is pioneering a first-of-its-kind diagnostic platform that combines menstrual fluid analysis with peripheral blood and AI-powered multi-omics to identify the root causes of chronic conditions like endometriosis, PCOS, and perimenopause.
The Biological Signal: Tapping Into Menstrual Fluid
Historically, the healthcare system has treated female biology as episodic and secondary, often dismissing symptoms like chronic pelvic pain as “normal stress”. Xella is changing this paradigm by utilizing biological signals that have been long ignored: menstrual fluid.
By analyzing this fluid alongside blood, Xella’s platform provides a depth of insight previously unavailable in a standard clinic:
- Fertility & Reproductive Health: Scores for egg quality and quantity, as well as personalized assessments of miscarriage risk.
- Hormonal Milestones: Specific staging for perimenopause and tailored guidance for Hormone Replacement Therapy (HRT) personalization.
- Oncology & Longevity: Genetic predispositions for reproductive cancers and insights into whole-body aging.
The “Know Your Code
” Model: Concierge Care at Scale
Xella’s mission, centered on the phrase “Know Your Code,” moves women’s health from symptom-based reactions to proactive foresight.
The platform integrates three core pillars:
- Multi-Omic Diagnostics: Advanced testing that looks at the interaction between genes, proteins, and metabolites.
- Longitudinal Data: Continuous tracking of biological changes over every life stage.
- Clinician-Led Guidance: Every user works with a dedicated clinician-coach, supported by AI, to translate complex biological data into actionable health outcomes.
Spring 2026 Launch
With a 10,000-person waitlist already forming ahead of its Spring 2026 launch, Xella is demonstrating a rare level of consumer “appetite” for data-driven women’s health.
“Our mission is to give women the answers and care they have always deserved,” said Kelly Lacob, Co-Founder & CEO of Xella. “Xella is building the infrastructure to decode female biology–getting to the root cause of conditions that uniquely, differently or disproportionately affect women, many of which suffer from an unacceptably poor standard of care today. Every woman who comes to Xella works with a dedicated clinician-coach, supported by AI, to ensure that the complex data we analyze translates into meaningful, actionable health outcomes rather than more noise. This funding allows us to accelerate product development and prepare for our first launch.”
